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A tumor, such as a dermatofibroma, causes consternation among many patients, but it rarely creates
problems on its own. Also called a histiocytoma, it remains one of the most common mesenchymal
growths. Its etiology is unknown with the previous theory that it is a dermal response to injury, such as
an insect bite, being challenged. As much as patients like to blame spiders or other arthropods for
traumatizing an arm or leg, no definitive explanation is available for its etiology.
This lesion seems more likely to be a neoplastic process due to the persistent nature of the lesion, the
frequency of local recurrence of some variants, and the clonal proliferative growth suggested by several
cytogenetic studies (1, 2). Clonality, by itself, is not necessarily synonymous with a neoplastic process, as
has been demonstrated in several inflammatory conditions, including atopic dermatitis, psoriasis, and
lichen sclerosis (2).
A dermatofibroma represents a benign dermal and often superficial subcutaneous proliferation of oval
cells, appearing as histiocytes and spindle-shaped cells resembling fibroblasts and myofibroblasts (3). It
occurs four times more often in women and is found in patients of any age, while nearly 80% of the
patients are between the ages of 20 and 49 years (4).

CLINICAL FINDINGS
A dermatofibroma typically arises slowly and as a solitary, 0.5- to 1-cm nodule, frequently yellowish
brown, and slightly scaly. Fig 1 It is most often found on an extremity, particularly the leg; however, the
palm, sole, fingers, genitalia, head and neck are not exempt. Its color may range from pink to red or
even to tan. Variations include a diameter, larger than 5 cm (5). It is usually a solitary lesion, but several
dermatofibromas may also be present, only rarely multiple (i.e., 15 or more) tumors, most frequently in
the setting of an autoimmune disease or altered immunity.
The diagnosis is easily made on inspection, with palpation revealing a hard nodule. If the overlying
epidermis is squeezed, the “dimple sign” will be seen due to tethering of the overlying epidermis to the

underlying lesion further confirming the diagnosis. This has also been called the Fitzpatrick sign and may
also be elicited by placing an ice cube over the lesion. (6)
A dermatofibroma is usually asymptomatic, but itching and pain are occasionally noted. Significant
trauma may cause ulceration.
The differential diagnosis is extensive but some lesions that might offer confusion, due to similarity of
appearance and consistency, are listed in Table 1. A tumor that might warrant excision to prove its
benign nature is a juvenile xanthogranuloma, where feeling the firm consistency will discount this lesion.
Palpation of one or more hard nodules especially on the trunk may raise the suspicion of
dermatofibrosarcoma protuberans, which can be differentiated by histopathology and
immunohistochemical testing. Traumatizing the lesion with subsequent erosion and ulceration may lead
to the misdiagnosis of squamous cell carcinoma or even atypical fibroxanthoma.

Table 1. Differential diagnosis of dermatofibroma.
Differential Diagnosis of Dermatofibroma
Melanocytic nevus
Blue nevus
Dermatofibrosarcoma protuberans
Juvenile xanthogranuloma
Keloid and hypertrophic scar
Keratoacanthoma
Leiomyoma
Malignant melanoma
Mastocytosis
Metastatic carcinoma of the skin
Neurilemoma
Pilomatrixoma
Prurigo nodularis
Spitz nevus
Squamous cell carcinoma
Atypical fibroxanthoma

Diagnosis
The diagnosis of a dermatofibroma is predominantly clinical. Dermatoscopy may be useful, when
revealing the most common pattern of a peripheral pigment network, along with a central white area
(7). In the case of any diagnostic uncertainty, an excisional biopsy with removal of the subcutaneous fat
would be indicated.
Histopathologic examination will reveal epidermal hyperplasia and hyperpigmetation of the basal cell
layer (“dirty fingernail” sign). The bulk of the tumor is within the mid-portion of the dermis without any

capsule formation. (Figs 2 and 3)Whorling fascicles of spindle cell proliferation with excessive collagen
deposition are characteristic. Some histologic variants of dermatofibroma have been described, as seen
in Table 2; however, the clinical picture is generally within the characteristic limits. Results from
immunohistochemical testing with antibodies to factor XIIIa are frequently positive in dermatofibroma.

Table 2. Histologic variants of dermatofibroma.
Histologic Variants of Dermatofibroma
Cellular (8)
Aneurysmal(9)
Atypical (dermatofibroma with monster cells)(10)
Epithelioid(11)
Atrophic(12)
Polypoid(13)
Dermatofibroma with spreading satellitosis (14)
Deep (subcutaneous) dermatofibroma

Treatment
A dermatofibroma is considered a benign lesion with a good prognosis. Although unusually rapid
growth may occur, most dermatofibromas remain static for many years. Spontaneous regression has
been reported which may result in post inflammatory hypopigmentation. Aggressive subtypes (cellular,
aneurysmal, atypical, and deep/subcutaneous) locally recur in up to 20% of the patients and rarely
metastasize. Although these variants are definitely diagnosed histopathologically, some clinical findings
may raise suspicion. For example, an abnormally large size of the lesion, especially measuring more than
5cm and rapid growth, may be indicative of a cellular or aneurysmal dermatofibroma. An unusual
appearance mimicking a vascular tumor can be a leading sign to an aneurysmal subtype.
No treatment is usually necessary for dermatofibromas. The scar resulting from excision is sometimes
more noticeable than the original lesion especially on the leg, so simple reassurance that the lesion is
benign may be indicated. Complete excision, including the subcutaneous fat, is ideal for symptomatic
ones, where a cosmetically unacceptable lesion may be the end result of intervention done at the
request of the patient. Superficially shaving of the lesion or cryosurgery can be attempted; however,
recurrences are more likely, and the cosmetic results are not necessarily better. Intralesional steroid
injections have been used with variable results. Carbon dioxide laser surgery for multiple facial

dermatofibromas has also been utilized (15), while an effective and safe therapeutic option could be use
of the pulsed dye laser (PDL) (16).
Conclusions

A dermatofibroma remains slightly more than a cosmetic nuisance. If it looks within normal
limits, excision just for cosmetic purposes is not recommended; however, if any uncertainty
exists about an unusual appearance, an abnormally large size, any irregularity, or unusual
location, excision should be considered. In these circumstances, the lesion might be better
being studied by the dermatopathologist, instead of remaining on the patient’s body.
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